<DOC>
	<DOCNO>NCT01956812</DOCNO>
	<brief_summary>The double-blind , randomize phase 3 study 90Y-clivatuzumab tetraxetan low-dose gemcitabine , versus placebo low-dose gemcitabine metastatic pancreatic cancer patient progress least 2 prior therapy metastatic cancer ( 1 gemcitabine-containing regimen ) .</brief_summary>
	<brief_title>Phase 3 Trial 90Y-Clivatuzumab Tetraxetan &amp; Gemcitabine v Placebo &amp; Gemcitabine Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma pancreas Metastatic disease Received least two prior systemic cytotoxic chemotherapy regimens unresectable , locally advanced metastatic disease . At least one prior systemic cytotoxic chemotherapy regimens unresectable , locally advanced metastatic disease must contain gemcitabine meet follow criterion : Completed least one cycle treatment Received gemcitabine administer minimum dose 800 mg/m2 per week first cycle treatment Progressed receive gemcitabine regimen within 3 month complete gemcitabine Progression document , Preferentially radiologically tumor growth new lesion , Clear symptomatic deterioration support least two follow clinical criterion : ≥ 10 % worsen KPS ≥ 1 worsen ECOG ; increase weakness fatigue ; progressive weight loss ; new/worsening pain require increase pain medication ; new/worsening jaundice , nausea , vomit ; new/worsening ascites pleural effusion ; physical laboratory finding consistent disease progression . KPS &gt; /= 70 Adequate bone marrow function Adequate hepatic function Adequate renal function CNS metastatic disease Bulky disease ( single mass &gt; 10 cm ) . &gt; Grade 2 nausea vomiting , and/or sign intestinal obstruction . Prior external beam irradiation field include 30 % red bone marrow . Patients clinically significant severe cardiorespiratory disease . Please consult clinical trial site full detailed list specific inclusion/exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>clivatuzumab tetraxetan</keyword>
	<keyword>90Y-clivatuzumab tetraxetan</keyword>
	<keyword>IMMU-107</keyword>
</DOC>